Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

S2159000

Sulfinpyrazone

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

(±)-Sulfinpyrazone, 1,2-Diphenyl-4-(phenylsulfinylethyl)-3,5-pyrazolidinedione, Diphenylpyrazone

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C23H20N2O3S
Numéro CAS:
57-96-5
Poids moléculaire :
404.48
Numéro MDL:
MFCD00057279
Code UNSPSC :
41116107
ID de substance PubChem :
329824510
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

sulfinpyrazone

Fabricant/nom de marque

EDQM

Application(s)

cleaning products
cosmetics
food and beverages
personal care
pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c3ccccc3)c4ccccc4

InChI

1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2

Clé InChI

MBGGBVCUIVRRBF-UHFFFAOYSA-N

Informations sur le gène

human ... SLC22A12(116085)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Sulfinpyrazone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302

Conseils de prudence

P301 + P312 + P330

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

D H Solomon et al.
Annals of the rheumatic diseases, 67(5), 609-613 (2007-08-31)
Uric acid lowering therapy (UALT) is considered a chronic treatment for gout. Relatively little is known about adherence to UALT. We assessed adherence with UALT over a 1-year study period among 9823 older adults enrolled in a pharmacy benefit program.
Mei-Ling Yang et al.
Free radical research, 36(6), 685-693 (2002-08-16)
Sulfinpyrazone, a potent uricosuric drug, was tested in vitro for its scavenging action against oxygen free radicals. In this study, sulfinpyrazone was able to scavenge 1,1-diphenyl-2-picrylhydrazyl radical with IC50 value of 29.82 micrograms/ml compared to butylated hydroxytoluene (BHT, IC50 value
James M May et al.
Free radical biology & medicine, 39(11), 1449-1459 (2005-11-09)
To test whether ascorbic acid might be involved in the antioxidant defenses of inflammatory cells, we studied ascorbate uptake and recycling by quiescent and lipopolysaccharide-activated RAW264.7 murine macrophages. These cells concentrated ascorbate 100-fold in overnight culture, achieving steady-state concentrations of
Sharon L Ripp et al.
Drug metabolism and disposition: the biological fate of chemicals, 34(10), 1742-1748 (2006-07-14)
Cytochrome P4503A4 (CYP3A4) is the principal drug-metabolizing enzyme in human liver. Drug-drug interactions (DDIs) caused by induction of CYP3A4 can result in decreased exposure to coadministered drugs, with potential loss of efficacy. Immortalized hepatocytes (Fa2N-4 cells) have been proposed as
Zhengrong Zhu et al.
Journal of biomolecular screening, 12(2), 248-254 (2007-01-30)
Cryopreserved, transiently transfected HepG2 cells were compared to freshly transfected HepG2 cells for use in a pregnane X receptor (PXR) transactivation assay. Assay performance was similar for both cell preparations; however, cryopreserved cells demonstrated less interassay variation. Validation with drugs
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique